Exploration of the benefits and resistance mechanisms of immunotherapy based on PD-L1 expression, circulating tumor DNA and T-cell receptor profiles in advanced gastric cancer

These findings suggest the different efficacy of first-line treatment regimens across varying levels of PD-L1 expression, and the molecular characteristics of patients with long-term benefits from immunotherapy.